Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLYS Mineralys Therapeutics, Inc.

Post-Mkt 04-07 19:45:25 EDT

28.31

+0.08

+0.28%

盘后28.31

+0.000.00%

17:06 EDT

High28.95	Low26.73	Vol2.06M
Open27.71	D1 Closing28.23	Amplitude7.86%
Mkt Cap2.33B	Tradable Cap1.71B	Total Shares82.40M
T/O58.05M	T/O Rate3.40%	Tradable Shares60.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":28.31,"timestamp":1775592000000,"preClose":28.23,"halted":0,"volume":2060543,"hourTrading":{"tag":"盘后","latestPrice":28.31,"preClose":28.31,"latestTime":"17:06 EDT","volume":412366,"amount":11674104.964862,"timestamp":1775596013473,"change":0,"changeRate":0,"amplitude":0.000706},"delay":0,"changeRate":0.0028338646829613283,"floatShares":60570600,"shares":82399500,"eps":-2.29,"marketStatus":"Post-Mkt","change":0.08,"latestTime":"04-07 19:45:25 EDT","open":27.71,"high":28.95,"low":26.73,"amount":58054925.35476799,"amplitude":0.07864,"askPrice":30.6,"askSize":299,"bidPrice":26.08,"bidSize":80,"shortable":3,"etf":0,"ttmEps":-2.29,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1775606400000},"marketStatusCode":4,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":28.23,"preHourTrading":{"tag":"盘前","latestPrice":28.4,"preClose":28.23,"latestTime":"09:09 EDT","volume":336,"amount":9501.74064,"timestamp":1775567343087,"change":0.17,"changeRate":0.006022,"amplitude":0.053135},"postHourTrading":{"tag":"盘后","latestPrice":28.31,"preClose":28.31,"latestTime":"17:06 EDT","volume":412366,"amount":11674104.964862,"timestamp":1775596013473,"change":0,"changeRate":0,"amplitude":0.000706},"volumeRatio":1.324357,"optionData":{"bulkOrders":[{"symbol":"MLYS","call":true,"expireDate":1781755200000,"strike":"35.0","timestamp":1775570699883,"price":2.97,"volume":1768,"amount":525096,"type":"+"},{"symbol":"MLYS","call":false,"expireDate":1781755200000,"strike":"20.0","timestamp":1775570699883,"price":1.4,"volume":1768,"amount":247520,"type":"-"}]},"impliedVol":0.9141,"impliedVolPercentile":0.628},"requestUrl":"/m/hq/s/MLYS/tweets","defaultTab":"tweets","newsList":[{"id":"2624638493","title":"Mineralys CEO Jon Congleton disposes of USD 2.0 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624638493","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624638493?lang=en_us&edition=fundamental","pubTime":"2026-04-03 06:55","pubTimestamp":1775170521,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics CEO Jon Congleton sold 75,000 common shares on March 31, 2026.Sales were executed at weighted-average prices of $25.5, $26.54, and $27.05.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLXDljy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys CEO Jon Congleton disposes of USD 2.0 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624863849","title":"Mineralys director Daphne Karydas disposes of common shares worth $0.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624863849","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624863849?lang=en_us&edition=fundamental","pubTime":"2026-04-03 06:53","pubTimestamp":1775170418,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics director Daphne Karydas sold 3,000 shares on March 31 at USD 25.Separate transaction showed exercise of stock options for 3,000 shares at USD 12.02.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL9wC1pj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624359530","title":"RA Capital Management acquires $8.8 million Mineralys Therapeutics shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624359530","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624359530?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:21","pubTimestamp":1774988485,"startTime":"0","endTime":"0","summary":"RA Capital Management reported purchases of Mineralys Therapeutics common stock.Holdings rose to about 5.8 million shares held indirectly.Peter Kolchinsky, manager, signed filing on behalf of RA Capital entities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLFMV3Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management acquires $8.8 million Mineralys Therapeutics shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623880795","title":"BUZZ-Immunic rises after board hire of MS drug veteran","url":"https://stock-news.laohu8.com/highlight/detail?id=2623880795","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623880795?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:55","pubTimestamp":1774954543,"startTime":"0","endTime":"0","summary":"BUZZ-Immunic rises after board hire of MS drug veteran** Shares of biotech firm Immunic IMUX.O rise 5% to $1.08 premarket **  Co says it appointed Jon Congleton to its board; he helped launch Teva’s multiple sclerosis drug Copaxone in the United States** Congleton has also served as CEO of Mineralys Therapeutics, Impel NeuroPharma and Nivalis Therapeutics,** Adds it is developing vidofludimus calcium, an oral experimental drug for relapsing multiple sclerosis, a form of the disease with recurring flareups** Co says latestage study readouts for the drug are expected by the end of 2026** Multiple sclerosis is a disease in which the immune system attacks nerves, leading to problems with movement and vision** Shares fell ~47% in 2025  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL4N40J0WQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU0109394709.USD","LU2462157665.USD","SG9999001176.SGD","IE0002141913.USD","LU2362541273.HKD","IE00B19Z9P08.USD","LU0889565916.HKD","IE0009355771.USD","SGXZ57979304.SGD","LU2324357040.USD","IE00B4R5TH58.HKD","LU1093756325.SGD","IE00B894F039.SGD","BK4532","LU0079474960.USD","IE00B19Z3B42.SGD","LU1035775433.USD","IE00B2B36J28.USD","LU2456880835.USD","LU2417539215.USD","LU0234570918.USD","LU0289739699.SGD","LU2236285917.USD","IE00BFTCPJ56.SGD","LU2362541513.USD","IMUX","IE00B19Z3581.USD","LU1674673428.USD","IE00BZ9MQY76.HKD","LU1585245621.USD","VRTX","LU1093756168.USD","LU0417517546.SGD","BK4588","BK4567","MLYS","LU1430594728.SGD","SG9999001176.USD","LU0256863811.USD","LU0823416689.USD","BK4533","BK4585","BK4139","LU1778281490.HKD","IE0002270589.USD","LU2362540622.SGD","LU1069344957.HKD","SG9999013999.USD","LU1674673691.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064682","title":"Mineralys appoints Jeffrey A. Munsie as chief legal officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064682","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064682?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:03","pubTimestamp":1774353804,"startTime":"0","endTime":"0","summary":"Munsie most recently served as chief legal officer and secretary at Orbital Therapeutics.Earlier roles included legal leadership positions at Concert Pharmaceuticals and Merrimack Pharmaceuticals.He began his career in the corporate department at Wilmer Cutler Pickering Hale and Dorr in Boston.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL886Qj7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","SG9999014005.SGD","NDAQ","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BN0W2V16.EUR","MLYS","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4112","LU2210149790.SGD","BK4139","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621713061","title":"Mineralys Therapeutics Appoints Jeffrey a. Munsie as Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621713061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621713061?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUA9RZ42F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621384064","title":"Press Release: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621384064","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621384064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353600,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., March 24, 2026  -- Mineralys Therapeutics, Inc. , a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease , obstructive sleep apnea  and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A. Munsie as Chief Legal Officer.\"Jeff brings deep life sciences experience across critical stages of growth, from preclinical through commercialization,\" said Jon Congleton, Chief Executive Officer of Mineralys. \"His strategic counsel, strong leadership, and proven track record will be instrumental in strengthening our legal and compliance capabilities.\". Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, hi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621275497","title":"Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA Acceptance - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2621275497","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621275497?lang=en_us&edition=fundamental","pubTime":"2026-03-23 14:09","pubTimestamp":1774246160,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. recently reported that its 2025 fourth-quarter net loss narrowed to US$32.23 million from US$48.95 million a year earlier, while the U.S. FDA accepted its New Drug Application for lorundrostat in adult hypertension with a PDUFA action date of December 22, 2026.\nThe combination of reduced annual net loss to US$154.65 million and FDA review acceptance for lorundrostat marks a shift toward a more advanced, late-stage profile for Mineralys as it moves closer to a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/mineralys-therapeutics-mlys-is-down-81-after-narrowed-loss-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/mineralys-therapeutics-mlys-is-down-81-after-narrowed-loss-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","LABU","MLYS","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620492319","title":"Mineralys CMO David Malcom Rodman disposes of USD 557,000 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620492319","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620492319?lang=en_us&edition=fundamental","pubTime":"2026-03-17 05:20","pubTimestamp":1773696050,"startTime":"0","endTime":"0","summary":"David Malcom Rodman, Chief Medical Officer, reported a disposal of common shares of Mineralys Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL64nQ70:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys CMO David Malcom Rodman disposes of USD 557,000 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620749447","title":"BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620749447","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620749447?lang=en_us&edition=fundamental","pubTime":"2026-03-17 05:05","pubTimestamp":1773695124,"startTime":"0","endTime":"0","summary":"BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)March 16 (Reuters) - Mineralys Therapeutics Inc MLYS.O:MINERALYS THERAPEUTICS REPORTS INDUCEMENT AWARDS UNDER","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUABMZSCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620499912","title":"Mineralys Therapeutics grants inducement equity awards covering 48,860 shares under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620499912","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620499912?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:09","pubTimestamp":1773691758,"startTime":"0","endTime":"0","summary":"Mineralys reported inducement equity awards under its 2025 Employment Inducement Incentive Award Plan for a new non-executive employee. The company granted a stock option covering 27,920 shares and restricted stock units covering 20,940 shares. The stock option vests over four years, with 25% vesting after one year and the remainder vesting monthly thereafter. The restricted stock units vest over four years, with 25% vesting on each annual anniversary.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL1z4zGf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014005.SGD","BK4112","SG9999014013.SGD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BKPKM429.USD","BK4588","MLYS","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014039.USD","LU2210149790.SGD","SG9999014021.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620460826","title":"Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620460826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620460826?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:40","pubTimestamp":1773679205,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS – Research Report...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mineralys-therapeutics-inc-mlys-and-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mineralys-therapeutics-inc-mlys-and-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","APRE","MLYS","BK4139","BK4581","LU0128526141.USD","BK4588","XBI","XLV","LABU","BK4137","BK4585","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619227581","title":"Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2619227581","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619227581?lang=en_us&edition=fundamental","pubTime":"2026-03-15 00:36","pubTimestamp":1773506171,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Mineralys Therapeutics, Inc., with a price target of $55.0...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mineralys-therapeutics-inc-mlys-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mineralys-therapeutics-inc-mlys-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128525929.USD","LU1035773651.USD","LU0149725797.USD","IE00B19Z3B42.SGD","LU2361044865.SGD","LU0175139822.USD","LU0070302665.USD","LU0154236417.USD","LU1069347547.HKD","LU0072461881.USD","LU0742534661.SGD","LU0640476718.USD","BK4139","LU0648001328.SGD","LU0787776722.HKD","LU0052756011.USD","LU0251142724.SGD","BK4207","LU0128525689.USD","LU1267930227.SGD","LU0314106906.USD","LU1363072403.SGD","BK4588","LU0106831901.USD","LU2361044949.HKD","IE0002270589.USD","LU0162691827.USD","LU1506573853.SGD","LU0267386448.USD","LU0048573561.USD","LU0208291251.USD","LU1267930573.SGD","LU0310800965.SGD","LU0256863811.USD","LU0251131958.USD","LU1668664300.SGD","LU0320765489.SGD","IE00B19Z3581.USD","LU1280957306.USD","BK4501","LU0310799852.SGD","LU1201861249.SGD","LU1814569148.SGD","LU2461242641.AUD","IE000M9KFDE8.USD","MLYS","LU0708994859.HKD","LU0029864427.USD","LU0942090050.USD","LU0477156953.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154474290","title":"Stock Track | Mineralys Therapeutics Soars 5.26% Intraday on Bank of America's Buy Rating Reiteration","url":"https://stock-news.laohu8.com/highlight/detail?id=1154474290","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154474290?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:48","pubTimestamp":1773409708,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. (MLYS) saw its stock price surge 5.26% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.The price increase...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619194575","title":"Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194575?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:56","pubTimestamp":1773402989,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Mineralys Therapeutics, Inc. yesterday and set a price target of $51.0...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-buy-rating-for-mineralys-therapeutics-inc-mlys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-buy-rating-for-mineralys-therapeutics-inc-mlys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAC","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619155241","title":"Mineralys Therapeutics Q4 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155241","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619155241?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:14","pubTimestamp":1773346469,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics  reported a Q4 loss late Thursday of $0.40 per diluted share, narrowing from a loss of $0.98 a year earlier.Analysts polled by FactSet expected a loss of $0.52.As of Dec. 31, the company had cash and cash equivalents of $656.6 million, expected to be adequate to fund its planned clinical trials and support corporate operations through 2028.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLYS","BK4139","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619155210","title":"Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155210","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619155210?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:12","pubTimestamp":1773346372,"startTime":"0","endTime":"0","summary":"Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618447969","title":"Mineralys Therapeutics Inc  expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2618447969","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618447969?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:32","pubTimestamp":1773174725,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Inc  expected to post a loss of53cents a share - Earnings Preview Mineralys Therapeutics Inc MLYS.OQ MLYS.O is expected to  show no change in quarterly revenue when it reports  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL8N3ZY2KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618608703","title":"Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea","url":"https://stock-news.laohu8.com/highlight/detail?id=2618608703","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618608703?lang=en_us&edition=fundamental","pubTime":"2026-03-10 07:14","pubTimestamp":1773098040,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics said its drug lorundrostat didn't meaningfully reduce sleep apnea in a Phase 2 trial.The biopharmaceutical company said Monday that the treatment didn't demonstrate a reduction in the Apnea-Hypopnea Index, which measures the number of times breathing stops or becomes shallow during an hour of sleep.Shares fell 3%, to $26.35, in after-hours trading.Lorundrostat did show meaningful reductions in blood pressure and had a meaningful safety profile, Chief Executive Jon Congleton said.The trial involved 48 patients and lasted four weeks.The Radnor, Pa., company also said the Food and Drug Administration accepted the new drug application for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs.The FDA has assigned a Prescription Drug User Fee Act target action date of Dec. 22.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","MLYS","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618672888","title":"FDA accepts Mineralys Therapeutics’ lorundrostat NDA with Dec. 22, 2026 PDUFA date","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672888","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672888?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:30","pubTimestamp":1773088234,"startTime":"0","endTime":"0","summary":"The FDA accepted Mineralys Therapeutics’ NDA for lorundrostat to treat adults with hypertension in combination with other antihypertensive drugs. The agency set a PDUFA target action date of December 22, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL8Q95w1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU0314104364.USD","IE00BKPKM429.USD","LU2095319765.USD","SG9999014005.SGD","LU2210150020.SGD","SG9999014013.SGD","BK4588","BK4139","MLYS","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","SG9999014039.USD","BK4585","BK4112","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mineralystx.com;www.ir.mineralystx.com","stockEarnings":[{"period":"1week","weight":0.2008},{"period":"1month","weight":0.0617},{"period":"3month","weight":-0.2095},{"period":"6month","weight":-0.2469},{"period":"1year","weight":1.2766},{"period":"ytd","weight":-0.2221}],"compareEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.0211},{"period":"1year","weight":0.3041},{"period":"ytd","weight":-0.0337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.014493},{"month":2,"riseRate":0.333333,"avgChangeRate":0.081442},{"month":3,"riseRate":0.25,"avgChangeRate":0.095856},{"month":4,"riseRate":0.25,"avgChangeRate":-0.063832},{"month":5,"riseRate":1,"avgChangeRate":0.0733},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.014247},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.022154},{"month":8,"riseRate":0.666667,"avgChangeRate":0.001437},{"month":9,"riseRate":0.333333,"avgChangeRate":0.388697},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.001589},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.0429},{"month":12,"riseRate":0.333333,"avgChangeRate":0.032291}],"exchange":"NASDAQ","name":"Mineralys Therapeutics, Inc.","nameEN":"Mineralys Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mineralys Therapeutics, Inc.,MLYS,Mineralys Therapeutics, Inc.股票,Mineralys Therapeutics, Inc.股票老虎,Mineralys Therapeutics, Inc.股票老虎国际,Mineralys Therapeutics, Inc.行情,Mineralys Therapeutics, Inc.股票行情,Mineralys Therapeutics, Inc.股价,Mineralys Therapeutics, Inc.股市,Mineralys Therapeutics, Inc.股票价格,Mineralys Therapeutics, Inc.股票交易,Mineralys Therapeutics, Inc.股票购买,Mineralys Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}